Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001225993 | SCV001398288 | uncertain significance | not provided | 2023-03-30 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 953664). This variant has not been reported in the literature in individuals affected with ERBB2-related conditions. This variant is present in population databases (rs767216520, gnomAD 0.07%), and has an allele count higher than expected for a pathogenic variant. This sequence change replaces lysine, which is basic and polar, with methionine, which is neutral and non-polar, at codon 591 of the ERBB2 protein (p.Lys591Met). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ERBB2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV005014262 | SCV005646004 | uncertain significance | Glioma susceptibility 1; Ovarian cancer; Gastric cancer; Lung cancer; Visceral neuropathy, familial, 2, autosomal recessive | 2024-01-10 | criteria provided, single submitter | clinical testing |